Pattern of macrovascular invasion in patients with hepatocellular carcinoma influences treatment and outcome

Platelet count as a predictor of vascular invasion and extrahepatic metastasis in hepatocellular carcinoma: A systematic review and meta-analysis

“…34 articles were assessed for eligibility through full-text search and 15 were further eliminated. A total of 16 articles [ 8 , 13 , [18] , [19] , [20] , [21] , [22] , [23] , [24] , [25] , [26] , [27] , [28] , [29] , [30] ] met the selection criteria, and their basic characteristics were presented in Table 1 . Lee et al analyzed duplicate population in two articles [ 35 , 36 ] , and the article with relatively small sample size was excluded [ 36 ].…”

“…Portal vein tumor thrombus (PVTT) is a common form of VI, the proportion of which is ranged from 13% to 45% [ 7 ]. A large number of HCC patients presents macrovascular invasion (MaVI) at diagnosis or posttherapeutic recurrence [ 8 ]. In contrast, microvascular invasion (MVI) can only be determined by microscopic examination of the resected tumor [ 9 ].…”

Prognostic and predictive factors for locoregional and systemic therapies in hepatocellular carcinoma

“…39 Presence of MVI confers a prognosis of approximately 6 months in HCC and is associated with younger age at diagnosis, worse PS, high AFP and large primary tumours. 40 Pooled analysis of the Sorafenib Hepatocellular Carcinoma Assessment Randomised Protocol (SHARP) and Asia-Pacific (AP) trials of first-line sorafenib also confirmed the association of MVI with poor prognosis in patients treated with first-line sorafenib or placebo. 41…”

“…The presence of macrovascular invasion (MVI) – grossly recognisable invasion into medium or large vessels, including portal vein tumour thrombosis – is one of the defining features of BCLC‐C disease, serving as a contraindication to LT, liver resection and TACE, due to high rates of recurrence and EHS 39 . Presence of MVI confers a prognosis of approximately 6 months in HCC and is associated with younger age at diagnosis, worse PS, high AFP and large primary tumours 40 . Pooled analysis of the Sorafenib Hepatocellular Carcinoma Assessment Randomised Protocol (SHARP) and Asia‐Pacific (AP) trials of first‐line sorafenib also confirmed the association of MVI with poor prognosis in patients treated with first‐line sorafenib or placebo 41 …”